Cargando…

Regulatory considerations for paediatric drug evaluation in China

The regulatory guidelines for the research and development of paediatric drugs are still evolving in China. The formulation of the guidelines started from learning and borrowing existing experience, and gradually changed to the exploration and improvement of local guidelines, which was not only in l...

Descripción completa

Detalles Bibliográficos
Autores principales: Geng, Ying, Li, Qiang, Sun, Yan-Zhe, Zhang, Hao, Jiang, Yong-Lin, Wang, Li-Qing, Wu, Yue-E, Zhao, Wei, Yang, Zhi-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163445/
https://www.ncbi.nlm.nih.gov/pubmed/37130653
http://dx.doi.org/10.1136/bmjpo-2022-001666
_version_ 1785037882668351488
author Geng, Ying
Li, Qiang
Sun, Yan-Zhe
Zhang, Hao
Jiang, Yong-Lin
Wang, Li-Qing
Wu, Yue-E
Zhao, Wei
Yang, Zhi-Min
author_facet Geng, Ying
Li, Qiang
Sun, Yan-Zhe
Zhang, Hao
Jiang, Yong-Lin
Wang, Li-Qing
Wu, Yue-E
Zhao, Wei
Yang, Zhi-Min
author_sort Geng, Ying
collection PubMed
description The regulatory guidelines for the research and development of paediatric drugs are still evolving in China. The formulation of the guidelines started from learning and borrowing existing experience, and gradually changed to the exploration and improvement of local guidelines, which was not only in line with international standards but also had breakthroughs, innovations and Chinese characteristics. In this paper, the current setting of paediatric drug research and development in China and corresponding technical guidelines have been introduced from regulatory perspectives, and the accessibility of further improvement in regulatory strategies has also been discussed.
format Online
Article
Text
id pubmed-10163445
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-101634452023-05-07 Regulatory considerations for paediatric drug evaluation in China Geng, Ying Li, Qiang Sun, Yan-Zhe Zhang, Hao Jiang, Yong-Lin Wang, Li-Qing Wu, Yue-E Zhao, Wei Yang, Zhi-Min BMJ Paediatr Open Review The regulatory guidelines for the research and development of paediatric drugs are still evolving in China. The formulation of the guidelines started from learning and borrowing existing experience, and gradually changed to the exploration and improvement of local guidelines, which was not only in line with international standards but also had breakthroughs, innovations and Chinese characteristics. In this paper, the current setting of paediatric drug research and development in China and corresponding technical guidelines have been introduced from regulatory perspectives, and the accessibility of further improvement in regulatory strategies has also been discussed. BMJ Publishing Group 2023-05-02 /pmc/articles/PMC10163445/ /pubmed/37130653 http://dx.doi.org/10.1136/bmjpo-2022-001666 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review
Geng, Ying
Li, Qiang
Sun, Yan-Zhe
Zhang, Hao
Jiang, Yong-Lin
Wang, Li-Qing
Wu, Yue-E
Zhao, Wei
Yang, Zhi-Min
Regulatory considerations for paediatric drug evaluation in China
title Regulatory considerations for paediatric drug evaluation in China
title_full Regulatory considerations for paediatric drug evaluation in China
title_fullStr Regulatory considerations for paediatric drug evaluation in China
title_full_unstemmed Regulatory considerations for paediatric drug evaluation in China
title_short Regulatory considerations for paediatric drug evaluation in China
title_sort regulatory considerations for paediatric drug evaluation in china
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163445/
https://www.ncbi.nlm.nih.gov/pubmed/37130653
http://dx.doi.org/10.1136/bmjpo-2022-001666
work_keys_str_mv AT gengying regulatoryconsiderationsforpaediatricdrugevaluationinchina
AT liqiang regulatoryconsiderationsforpaediatricdrugevaluationinchina
AT sunyanzhe regulatoryconsiderationsforpaediatricdrugevaluationinchina
AT zhanghao regulatoryconsiderationsforpaediatricdrugevaluationinchina
AT jiangyonglin regulatoryconsiderationsforpaediatricdrugevaluationinchina
AT wangliqing regulatoryconsiderationsforpaediatricdrugevaluationinchina
AT wuyuee regulatoryconsiderationsforpaediatricdrugevaluationinchina
AT zhaowei regulatoryconsiderationsforpaediatricdrugevaluationinchina
AT yangzhimin regulatoryconsiderationsforpaediatricdrugevaluationinchina